ArticleCureus2025
Comparison of Levetiracetam Versus Sodium Valproate as a Monotherapy in Early Childhood Epilepsy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood epilepsy requires long-term management with antiepileptic drugs (AEDs) that are both effective and well-tolerated. Although levetiracetam and sodium valproate are widely used as monotherapies, comparative data on their efficacy and safety in pediatric populations are limited. This study aimed to evaluate and compare their effectiveness and tolerability in children with epilepsy over six months.
methodsA randomized controlled study was conducted involving 200 children aged 3 to 12 years with generalized or focal epilepsy. They were randomly assigned to receive either levetiracetam (n=100) or sodium valproate (n=100), and received sodium valproate at an initial dose of 30 mg/kg/day. Efficacy was defined as a threefold increase in seizure-free interval. Side effects were monitored monthly. Data were analyzed using SPSS version 29 with a significance threshold of p<0.05.
resultsSeizure control was achieved in 85% of children in the levetiracetam group and 73% in the sodium valproate group (p=0.037). Absence of side effects was reported in 31% of the levetiracetam group and 10% of the sodium valproate group (p=0.012). Weight gain occurred in 16 children (16.0%) in the sodium valproate group versus 5 children (5.0%) in the levetiracetam group. Other side effects, including hepatotoxicity, rash, somnolence, tremors, and behavioral changes, were comparable between the groups.
conclusionLevetiracetam appears to be more effective and better tolerated than sodium valproate for the management of pediatric epilepsy. These findings suggest that levetiracetam could be considered a preferred first-line monotherapy. However, further longitudinal studies are warranted to validate these outcomes over longer treatment durations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.